Important drug-nutrient interactions

Proceedings of the Nutrition Society

Volumn 69, Issue 4, 2010, Pages 551-557

  Mason, Pamela ^a  

^a Gwernesney   (United Kingdom)

Author keywords

Cytochrome P450 enzymes; Drugs; Interactions; Nutrients; Supplements

Indexed keywords

ALLOPURINOL; AMANTADINE; AMIODARONE; ANTICOAGULANT AGENT; ANTIHISTAMINIC AGENT; BACLOFEN; BENZATROPINE; CYPROHEPTADINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FISH OIL; FLUOXETINE; FOLIC ACID; GRISEOFULVIN; LEVODOPA; LITHIUM; METFORMIN; METRONIDAZOLE; MONOAMINE OXIDASE INHIBITOR; ORPHENADRINE; OXYBUTYNIN; PENICILLAMINE; PHENYTOIN; PYRIDOXINE; TERBINAFINE; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; WARFARIN;

BLOOD EXAMINATION; CELIAC DISEASE; CONFERENCE PAPER; CYSTIC FIBROSIS; DIET SUPPLEMENTATION; DIETARY INTAKE; DIETITIAN; DRUG EFFICACY; FOOD DRUG INTERACTION; GASTROINTESTINAL ABSORPTION; GRAPEFRUIT JUICE; HUMAN; HYPERICUM PERFORATUM; INCREASED APPETITE; NURSE; NUTRIENT; NUTRIENT UPTAKE; PHARMACIST; PHYSICIAN; TASTE; WEIGHT REDUCTION;

APPETITE; DIETARY SUPPLEMENTS; DRUG MONITORING; FOOD-DRUG INTERACTIONS; HERB-DRUG INTERACTIONS; HUMANS; NUTRITIONAL STATUS;

CITRUS X PARADISI;

EID: 79951941412     PISSN: 00296651     EISSN: 14752719     Source Type: Journal    
DOI: 10.1017/S0029665110001576     Document Type: Conference Paper

References (74)

1. Roe DA (1989) Diet and Drug Interactions. New York: Van Nostrand Reinhold.
2. Thomas JA (1995) Drug and nutrient interactions. Nutr Rev 53, 271-282.
3. Boullata JI, Barber JR (2004) A perspective on drugnutrient interactions. In Handbook of Drug-Nutrient Interactions, pp. 3-27 [JI Boullata and VT Armenti, editors]. New Jersey: Humana Press.
4. Santos CA, Boullata JI (2005) An approach to evaluating drug-nutrient interactions. Pharmacotherapy 25, 1789-1800. (Pubitemid 41790101)
5. Genser D (2008) Food and drug interaction: consequences for the nutrition/health status. Ann Nutr Metab 52, Suppl. 1, 29-32. (Pubitemid 351496702)
6. Leibovitch ER, Deamer RL, Sanderson LA (2004) Food- drug interactions: careful drug selection and patient counseling can reduce the risk in older patients. Geriatrics 59, 19-22, 32-33.
7. Mazokopakis EE, Giannakopoulos TG, Starakis IK (2008) Interaction between levothyroxine and calcium carbonate. Can Fam Physician 54, 39. (Pubitemid 351198351)
8. Singh N, Singh PN, Hershman JM (2000) Effect of calcium carbonate on the absorption of levothyroxine. JAMA 283, 2822-2825. (Pubitemid 30387827)
9. Martin J (editor) (2010) British National Formulary. Number
10. March 2010. London: BMJ Group and RPS Publishing.
11. Thomas DR (2009) Anorexia: aetiology, epidemiology and management in older people. Drugs Aging 26, 557-570.
12. Doty RL, Bromley SM (2004) Effects of drugs on olfaction and taste. Otolaryngol Clin North Am 37, 1229-1254. (Pubitemid 39572504)
13. Roberts CD, Dvoryanchikov G, Roper SD et al. (2009) Interaction between the second messengers cAMP and Ca2 + in mouse presynaptic taste cells. J Physiol 587, Pt 8, 1657-1668.
14. Shimada S, Ueda T, Ishida Y et al. (2006) Acid-sensing ion channels in taste buds. Arch Histol Cytol 69, 227-231.
15. Matsuo R (2000) Role of saliva in the maintenance of taste sensitivity. Crit Rev Oral Biol Med 11, 216-229.
16. Termanini B, Gibril F, Sutliff VE et al. (1998) Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am J Med 104, 422-430. (Pubitemid 28274845)
17. Sagar M, Janczewska I, Ljungdahl A et al. (1999) Effect of CYP2C19 polymorphism on serum levels of vitamin B12 in patients on long-term omeprazole treatment. Aliment Pharmacol Ther 13, 453-458. (Pubitemid 29176867)
18. Ruscin JM, Page RL II, Valuck RJ (2002) Vitamin B12 deficiency associated with histamine(2)-receptor antagonists and a proton-pump inhibitor. Ann Pharmacother 36, 812-816. (Pubitemid 34517409)
19. ÓNeil-Cutting MA, Crosby WH (1986) The effect of antacids on the absorption of simultaneously ingested iron. JAMA 255, 1468-1470. (Pubitemid 16119431)
20. Stewart CA, Termanini B, Sutliff VE et al. (1998) Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy. Aliment Pharmacol Ther 12, 83-98. (Pubitemid 28057410)
21. Potgieter MA, Potgieter JH, Venter C et al. (2007) Effect of oral aluminium hydroxide on iron absorption from iron(III)- hydroxide polymaltose complex in patients with iron deficiency anemia/a single-centre randomized controlled isotope study. Arzneimittelforschung 57, 392-400. (Pubitemid 47055990)
22. Chan L-N (2006) Drug-nutrient interactions. In Modern Nutrition in Health and Disease, pp. 1539-1553 [ME Shils, M Shike, AC Ross, B Caballero and RJ Cousins, editors]. Baltimore and Philadelphia: Lippincott, Williams, Wilkins.
23. Sturtzel B, Dietrich A, Wagner KH (2010) The status of vitamins B6, B12, folate, and of homocysteine in geriatric home residents receiving laxatives or dietary fiber. J Nutr Health Aging 14, 219-223.
24. Hoffbrand AV, Necheles TF (1968) Mechanism of folate deficiency in patients receiving phenytoin. Lancet 2, 528-530.
25. Rosenberg IH, Godwin HA, Streiff RR et al. (1968) Impairment of intestinal deconjugation of dietary folate. A possible explanation of megaloblastic anaemia associated with phenytoin therapy. Lancet 2, 530-532.
26. Houlihan CM, Scott JM, Boyle PH et al. (1972) The effect of phenytoin on the absorption of synthetic folic acid polyglutamate. Gut 13, 189-190.
27. Baugh CM, Krumdieck CL (1969) Effects of phenytoin on folic-acid conjugases in man. Lancet 2, 519-521.
28. Berg M (2004) Effects of antiepileptics on nutritional status. In Handbook of Drug-Nutrient Interactions, pp. 285-299 [JI Boullata and VT Armenti, editors]. New Jersey: Humana Press.
29. Fujita K (2004) Food-drug interactions via human cytochrome P450 3A (CYP3A). Drug Metabol Drug Interact 20, 195-217. (Pubitemid 40083055)
30. Girennavar B, Jayaprakasha GK, Patil BS (2007) Potent inhibition of human cytochrome P450 3A4, 2D6, and 2C9 isoenzymes by grapefruit juice and its furocoumarins. J Food Sci 72, C417-C421. (Pubitemid 47583547)
31. Dahan A, Altman H (2004) Food-drug interaction: grapefruit juice augments drug bioavailability - mechanism, extent and relevance. Eur J Clin Nutr 58, 1-9. (Pubitemid 38159306)
32. Kiani J, Imam SZ (2007) Medicinal importance of grapefruit juice and its interaction with various drugs. Nutr J 6, 33.
33. Bressler R (2006) Grapefruit juice and drug interactions. Exploring mechanisms of this interaction and potential toxicity for certain drugs. Geriatrics 61, 12-18.
34. Lundahl JU, Regardh CG, Edgar B et al. (1998) The interaction effect of grapefruit juice is maximal after the first glass. Eur J Clin Pharmacol 54, 75-81. (Pubitemid 28189404)
35. Lilja JJ, Kivisto KT, Neuvonen PJ (2000) Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clin Pharmacol Ther 68, 384-390.
36. Bailey DG, Dresser GK, Kreeft JH et al. (2000) Grapefruit- felodipine interaction: effect of unprocessed fruit and probable active ingredients. Clin Pharmacol Ther 68, 468-477.
37. Bailey DG, Dresser GK, Bend JR (2003) Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: comparison with grapefruit juice. Clin Pharmacol Ther 73, 529-537. (Pubitemid 37249123)
38. Malhotra S, Bailey DG, Paine MF et al. (2001) Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther 69, 14-23. (Pubitemid 32109323)
39. Schwarz UI, Johnston PE, Bailey DG et al. (2006) Impact of citrus soft drinks relative to grapefruit juice on ciclosporin disposition. Br J Clin Pharmacol 62, 485-491. (Pubitemid 44401532)
40. Andersson KE, Bratt L, Dencker H et al. (1976) Inhibition of tetracycline absorption by zinc. Eur J Clin Pharmacol 9, 131-134.
41. Lehto P, Kivisto KT, Neuvonen PJ (1994) The effect of ferrous sulphate on the absorption of norfloxacin, ciprofloxacin and ofloxacin. Br J Clin Pharmacol 37, 82-85. (Pubitemid 24204588)
42. Polk RE, Healy DP, Sahai J et al. (1989) Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother 33, 1841-1844. (Pubitemid 19266241)
43. Osman MA, Patel RB, Schuna A et al. (1983) Reduction in oral penicillamine absorption by food, antacid, and ferrous sulfate. Clin Pharmacol Ther 33, 465-470. (Pubitemid 13093766)
44. Lyle WH (1976) Penicillamine and iron. Lancet 2, 420.
45. Leonard JP, Desager JP, Beckers C et al. (1979) In vitro binding of various biological substances by two hypocholesterolaemic resins. Cholestyramine and colestipol. Arzneimittelforschung 29, 979-981. (Pubitemid 9214834)
46. Knodel LC, Talbert RL (1987) Adverse effects of hypolipidaemic drugs. Med Toxicol 2, 10-32. (Pubitemid 17001247)
47. Kulak CA, Borba VZ, Bilezikian JP et al. (2004) Bone mineral density and serum levels of 25 OH vitamin D in chronic users of antiepileptic drugs. Arq Neuropsiquiatr 62, 940-948. (Pubitemid 40013088)
48. Asherov J, Weinberger A, Pinkhas J (1977) Lack of response to vitamin D therapy in a patient with hypoparathyroidism under anticonvulsant drugs. Helv Paediatr Acta 32, 369-373. (Pubitemid 8235293)
49. Rubinger D, Korn-Lubetzki I, Feldman S et al. (1980) Delayed response to a alpha-hydroxycholecalciferol therapy in a case of hypoparathyroidism during anticonvulsant therapy. Isr J Med Sci 16, 772-774. (Pubitemid 11194280)
50. Collins N, Maher J, Cole M et al. (1991) A prospective study to evaluate the dose of vitamin D required to correct low 25- hydroxyvitamin D levels, calcium, and alkaline phosphatase in patients at risk of developing antiepileptic drug-induced osteomalacia. Q J Med 78, 113-122.
51. Lee RH, Lyles KW, Colon-Emeric C (2010) A review of the effect of anticonvulsant medications on bone mineral density and fracture risk. Am J Geriatr Pharmacother 8, 34-46.
52. Nakken KO, Tauboll E (2010) Bone loss associated with use of antiepileptic drugs. Expert Opin Drug Saf 2010, 4.
53. Prasad AS, Oberleas D, Moghissi KS et al. (1975) Effect of oral contraceptive agents on nutrients: II. Vitamins. Am J Clin Nutr 28, 385-391.
54. Hsu TH, Bianchine JR, Preziosi TJ et al. (1973) Effect of pyridoxine on levodopa metabolism in normal and parkinsonian subjects. Proc Soc Exp Biol Med 143, 578-581.
55. Mars H (1973) Metabolic interactions of pyridoxine, levodopa, and carbidopa in Parkinsońs disease. Trans Am Neurol Assoc 98, 241-245.
56. Duvoisin RC, Yahr MD, Cote LD (1969) Pyridoxine reversal of L-dopa effects in Parkinsonism. Trans Am Neurol Assoc 94, 81-84.
57. Greene RJ, Hall AD, Hider RC (1990) The interaction of orally administered iron with levodopa and methyldopa therapy. J Pharm Pharmacol 42, 502-504. (Pubitemid 20301489)
58. Jalili M, Dehpour AR (2007) Extremely prolonged INR associated with warfarin in combination with both trazodone and omega-3 fatty acids. Arch Med Res 38, 901-904. (Pubitemid 47513273)
59. Buckley MS, Goff AD, Knapp WE (2004) Fish oil interaction with warfarin. Ann Pharmacother 38, 50-52.
60. Bender NK, Kraynak MA, Chiquette E et al. (1998) Effects of marine fish oils on the anticoagulation status of patients receiving chronic warfarin therapy. J Thromb Thrombolysis 5, 257-261. (Pubitemid 28241452)
61. Izzo AA, Ernst E (2009) Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 69, 1777-1798.
62. Kober M, Pohl K, Efferth T (2008) Molecular mechanisms underlying St. Johńs wort drug interactions. Curr Drug Metab 9, 1027-1037.
63. Staatz CE, Goodman LK, Tett SE (2010) Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin Pharmacokinet 49, 141-175.
64. Eisenberg DM, Davis RB, Ettner SL et al. (1998) Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 280, 1569-1575. (Pubitemid 28520643)
65. Gulian C, Barnes J, Francis S (2002) Types and preferred sources of information concerning herbal medicinal products: face to face interviews with users of herbal medicinal products. Int J Pharm Pract 10, Suppl., R33.
66. Dergal JM, Gold JL, Laxer DA et al. (2002) Potential interactions between herbal medicines and conventional drug therapies used by older adults attending a memory clinic. Drugs Aging 19, 879-886. (Pubitemid 35440606)
67. Patterson R, Neuhouser M, Hedderson M et al. (2002) Types of alternative medicine used by patients with breast, colon, or prostate cancer: predictors, motives, and costs. J Altern Complement Med 8, 477-485. (Pubitemid 34994542)
68. Risa KJ, Nepon L, Justis JC et al. (2002) Alternative therapy use in HIV-infected patients receiving highly active antiretroviral therapy. Int J STD AIDS 13, 706-713.
69. Meyer T, Baisden CE, Roberson CR et al. (2002) Survey of preopeartive patients use of herbal products and other selected dietary supplements. Hosp Pharm 37, 1301-1306. (Pubitemid 36019356)
70. Peng CC, Glassman PA, Trilli LE et al. (2004) Incidence and severity of potential drug-dietary supplement interactions in primary care patients: an exploratory study of 2 outpatient practices. Arch Intern Med 164, 630-636. (Pubitemid 38392977)
71. Lee AH, Ingraham SE, Kopp M et al. (2006) The incidence of potential interactions between dietary supplements and prescription medications in cancer patients at a Veterans Administration Hospital. Am J Clin Oncol 29, 178-182. (Pubitemid 44270960)
72. Velicer CM, Ulrich CM (2008) Vitamin and mineral supplement use among US adults after cancer diagnosis: a systematic review. J Clin Oncol 26, 665-673. (Pubitemid 351264364)
73. Sood A, Sood R, Brinker FJ et al. (2008) Potential for interactions between dietary supplements and prescription medications. Am J Med 121, 207-211. (Pubitemid 351317929)
74. Loya AM, Gonzalez-Stuart A, Rivera JO (2009) Prevalence of polypharmacy, polyherbacy, nutritional supplement use and potential product interactions among older adults living on the United States-Mexico border: a descriptive, questionnaire- based study. Drugs Aging 26, 423-436.